NCT01272037 2026-03-18
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer
National Cancer Institute (NCI)
Phase 3 Active not recruiting
Clinical Trials
18 trialsNCT03978663 2026-02-20
TRIO
London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Phase NA Active not recruiting
NCT07407244 2026-02-17
AKRA
Institute of Oncology Ljubljana
Phase NA Active not recruiting
NCT02875314 2026-02-12
HeadStart4: Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors
Nationwide Children's Hospital
Phase 4 Active not recruiting
NCT03387553 2026-02-09
HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase EARLY_PHASE1 Active not recruiting
NCT05333874 2026-02-09
CIPHER Study: Pilot Study to Study the Role of ctDNA in Triple Negative and HER2 Positive Early Stage
Rutgers, The State University of New Jersey
Phase EARLY_PHASE1 Active not recruiting
NCT06660810 2026-01-15
Neoadjuvant Intralesional Injection of Talimogene Laherparepvec
University of Iowa
Phase 2 Active not recruiting
NCT07038122 2025-12-18
RESET
Sixth Affiliated Hospital, Sun Yat-sen University
Phase NA Active not recruiting
NCT00929214 2025-12-17
Aggressive Local Therapy for Limited Bone-Only Metastasis to Improve Progression-Free Survival in Breast Cancer Patients
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT05659251 2025-12-02
Serplulimab Combined With Chemotherapy in Patients With Resectable Esophageal Squamous Cell Carcinoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Active not recruiting
NCT05882513 2025-12-02
Serplulimab Combined With Chemotherapy in Patients With Resectable Non-small-cell Lung Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Active not recruiting
NCT04669496 2025-09-04
Phase II-III Clinical Trial of PD1 Antibody (Toripalimab), Lenvatinib and GEMOX Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors
Shanghai Zhongshan Hospital
Phase 2/3 Active not recruiting
NCT06876636 2025-07-29
Zoledronic Acid Combined With EC-T for Triple-Negative Breast Cancer
Xijing Hospital
Phase NA Active not recruiting
NCT06762158 2025-01-07
NCRT Combined With Sequential Perioperative PD-1 Inhibitor for LAESCC
RenJi Hospital
Phase NA Active not recruiting
NCT02124421 2024-11-19
CRS/HIPEC
Mercy Medical Center
Phase 2 Active not recruiting
NCT05724329 2024-09-19
Neoadjuvant Tislelizumab in Combination With Dasatinib and Quercetin in Resectable HNSCC (COIS-01)
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2 Active not recruiting
NCT02509286 2024-05-08
ESOPEC
University Hospital Schleswig-Holstein
Phase 3 Active not recruiting
NCT04085250 2024-04-23
Study of Nivolumab for Non-Small Cell Lung Cancer (Stage III) Following Neoadjuvant Chemotherapy Plus Nivolumab and Definitive Concurrent Chemoradiation Therapy
Sun Yat-sen University
Phase 2 Active not recruiting